BACKGROUND: The increasing availability of antiretroviral therapy (ART) has improved survival and quality of life for many infected with HIV, but can also engender drug resistance. This review summarizes the available information on drug resistance in adults in resource-limited settings. METHODS: The online databases PubMed and Google Scholar, pertinent conference abstracts and references from relevant articles were searched for publications available before November 2011. Data collected after ART rollout were reviewed. RESULTS: A total of 7 studies fulfilled the criteria for the analysis of acquired drug resistance and 22 fulfilled the criteria for the analysis of transmitted drug resistance (TDR). Acquired resistance was detected in 7.2% of patients on ART for 6-11 months, 11.1% at 12-23 months, 15.0% at 24-35 months, and 20.7% at ≥ 36 months. Multi-class drug resistance increased steadily with time on ART. The overall rate of TDR in all resource-limited countries studied was 6.6% (469/7,063). Patients in countries in which ART had been available for ≥ 5 years were 1.7 × more likely to have TDR than those living in a country where ART had been available for <5 years (P<0.001). The reported prevalence of TDR was 5.7% (233/4,069) in Africa, 7.6% (160/2,094) in Asia and 8.4% (76/900) in Brazil. CONCLUSIONS: The emergence of drug resistance following access to ART in resource-limited settings resembles what was seen in resource-rich countries and highlights the need for virological monitoring for drug failure, drug resistance testing and alternative drug regimens that have proven beneficial in these resource-rich settings.
BACKGROUND: The increasing availability of antiretroviral therapy (ART) has improved survival and quality of life for many infected with HIV, but can also engender drug resistance. This review summarizes the available information on drug resistance in adults in resource-limited settings. METHODS: The online databases PubMed and Google Scholar, pertinent conference abstracts and references from relevant articles were searched for publications available before November 2011. Data collected after ART rollout were reviewed. RESULTS: A total of 7 studies fulfilled the criteria for the analysis of acquired drug resistance and 22 fulfilled the criteria for the analysis of transmitted drug resistance (TDR). Acquired resistance was detected in 7.2% of patients on ART for 6-11 months, 11.1% at 12-23 months, 15.0% at 24-35 months, and 20.7% at ≥ 36 months. Multi-class drug resistance increased steadily with time on ART. The overall rate of TDR in all resource-limited countries studied was 6.6% (469/7,063). Patients in countries in which ART had been available for ≥ 5 years were 1.7 × more likely to have TDR than those living in a country where ART had been available for <5 years (P<0.001). The reported prevalence of TDR was 5.7% (233/4,069) in Africa, 7.6% (160/2,094) in Asia and 8.4% (76/900) in Brazil. CONCLUSIONS: The emergence of drug resistance following access to ART in resource-limited settings resembles what was seen in resource-rich countries and highlights the need for virological monitoring for drug failure, drug resistance testing and alternative drug regimens that have proven beneficial in these resource-rich settings.
Authors: A Cozzi-Lepri; A N Phillips; B Clotet; J Kjaer; V Von Wyl; G Kronborg; A Castagna; J R Bogner; J D Lundgren Journal: HIV Med Date: 2011-08-17 Impact factor: 3.180
Authors: Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Francesca Conradie; Mariette E Botes; Maureen Wellington; Akin Osibogun; Kim C E Sigaloff; Immaculate Nankya; Rob Schuurman; Ferdinand W Wit; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit Journal: Lancet Infect Dis Date: 2011-07-27 Impact factor: 25.071
Authors: Toshibumi Taniguchi; Diana Nurutdinova; Jessica R Grubb; Nur F Önen; Enbal Shacham; Michael Donovan; Edgar Turner Overton Journal: AIDS Res Hum Retroviruses Date: 2011-08-30 Impact factor: 2.205
Authors: Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman Journal: J Virol Date: 2008-03-19 Impact factor: 5.103
Authors: A Apisarnthanarak; T Jirayasethpong; C Sa-nguansilp; H Thongprapai; C Kittihanukul; A Kamudamas; A Tungsathapornpong; L M Mundy Journal: HIV Med Date: 2008-05 Impact factor: 3.180
Authors: Viktor von Wyl; Sabine Yerly; Philippe Bürgisser; Thomas Klimkait; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Hansjakob Furrer; Bernard Hirschel; Pietro L Vernazza; Patrick Francioli; Sebastian Bonhoeffer; Bruno Ledergerber; Huldrych F Günthard Journal: Clin Infect Dis Date: 2009-04-01 Impact factor: 9.079
Authors: Eduardo Sprinz; Eduardo M Netto; Maria Patelli; J S Lima; Maria Patelli J S Lima; Juvênao J D Furtado; Margareth da Eira; Roberto Zajdenverg; José V Madruga; David S Lewi; Alcyone A Machado; Rogério J Pedro; Marcelo A Soares Journal: AIDS Res Hum Retroviruses Date: 2009-09 Impact factor: 2.205
Authors: Michele W Tang; Soo-Yon Rhee; Silvia Bertagnolio; Nathan Ford; Susan Holmes; Kim C Sigaloff; Raph L Hamers; Tobias F Rinke de Wit; Herve J Fleury; Phyllis J Kanki; Kiat Ruxrungtham; Claudia A Hawkins; Carole L Wallis; Wendy Stevens; Gert U van Zyl; Weerawat Manosuthi; Mina C Hosseinipour; Nicole Ngo-Giang-Huong; Laurent Belec; Martine Peeters; Avelin Aghokeng; Torsak Bunupuradah; Sherri Burda; Patricia Cane; Giulia Cappelli; Charlotte Charpentier; Anoumou Y Dagnra; Alaka K Deshpande; Ziad El-Katib; Susan H Eshleman; Joseph Fokam; Jean-Chrysostome Gody; David Katzenstein; Donato D Koyalta; Johnstone J Kumwenda; Marc Lallemant; Lutgarde Lynen; Vincent C Marconi; Nicolas A Margot; Sandrine Moussa; Thumbi Ndung'u; Phillipe N Nyambi; Catherine Orrell; Jonathan M Schapiro; Rob Schuurman; Sunee Sirivichayakul; Davey Smith; Maria Zolfo; Michael R Jordan; Robert W Shafer Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: Angelica N Martins; Abdul A Waheed; Sherimay D Ablan; Wei Huang; Alicia Newton; Christos J Petropoulos; Rodrigo D M Brindeiro; Eric O Freed Journal: J Virol Date: 2015-10-28 Impact factor: 5.103
Authors: Emiko Urano; Sherimay D Ablan; Rebecca Mandt; Gary T Pauly; Dina M Sigano; Joel P Schneider; David E Martin; Theodore J Nitz; Carl T Wild; Eric O Freed Journal: Antimicrob Agents Chemother Date: 2015-10-19 Impact factor: 5.191
Authors: Ingrid A Beck; Wenjie Deng; Rachel Payant; Robert Hall; Roger E Bumgarner; James I Mullins; Lisa M Frenkel Journal: J Clin Microbiol Date: 2014-04-16 Impact factor: 5.948
Authors: Michael H Chung; Ingrid A Beck; Sandra Dross; Kenneth Tapia; James N Kiarie; Barbra A Richardson; Julie Overbaugh; Samah R Sakr; Grace C John-Stewart; Lisa M Frenkel Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega Journal: AIDS Date: 2014-11-28 Impact factor: 4.177